Last updated: February 19, 2026
This analysis provides key insights into patentability, enforceability, and claim scope for biopharmaceutical patents filed with the Austrian Patent Office (Österreichisches Patentamt). It examines current trends, relevant legal precedents, and procedural considerations to inform R&D and investment decisions.
What are the General Patentability Requirements for Biopharmaceuticals in Austria?
Biopharmaceutical inventions in Austria are subject to the general patentability requirements outlined in the Austrian Patent Act (Patentgesetz - PatG). These include novelty, inventive step, and industrial applicability. The European Patent Convention (EPC), to which Austria is a signatory, significantly influences Austrian patent law, particularly regarding subject matter eligibility and inventive step assessment.
Key Patentability Criteria:
- Novelty (Neuheit): An invention is novel if it has not been disclosed to the public before the filing date of the patent application [1]. For biopharmaceuticals, this often involves demonstrating a new active compound, a new formulation, a new medical use of a known compound, or a new method of producing a biological entity.
- Inventive Step (Erfindungshöhe): An invention involves an inventive step if, having regard to the state of the art, it is not obvious to a person skilled in the art [1]. This is a critical hurdle for biopharmaceutical patents, where incremental improvements or predictable modifications of known compounds may not meet the non-obviousness standard. The "person skilled in the art" in this field is assumed to have comprehensive knowledge of molecular biology, genetics, pharmacology, and medicine.
- Industrial Applicability (Gewerbliche Anwendbarkeit): The invention must be capable of being made or used in any kind of industry, including agriculture [1]. For biopharmaceuticals, this is generally straightforward, as therapeutic compounds and methods are inherently industrial.
- Patentable Subject Matter: While biological material itself is not patentable in its naturally occurring state, discoveries of new genes, proteins, or microorganisms, or new uses of such discoveries, can be patentable if they meet the criteria of novelty, inventive step, and industrial applicability [1]. The patentability of claims related to human sequences and genes has been refined through European Patent Office (EPO) case law, which is highly influential in Austria.
How Does Austrian Patent Law Address the Patentability of Biological Subject Matter?
Austrian patent law, largely harmonized with the EPC, addresses the patentability of biological subject matter through specific provisions and interpretations that reflect evolving scientific understanding and ethical considerations.
Specific Considerations for Biological Inventions:
- Discovery vs. Invention: A mere discovery of something that already exists in nature, such as a naturally occurring gene or protein, is not patentable. However, if the discovered biological material is isolated or obtained by means of a technical process, and if it is possible to identify its function, then it can be considered an invention and thus patentable, provided it meets the other patentability criteria [1]. This distinction is crucial. For example, isolating a previously unknown gene from a human body and demonstrating its function and utility constitutes an invention.
- Embryos and Human Cloning: The Austrian Patent Act explicitly excludes from patentability processes for cloning human beings and processes for modifying the germ line genetic identity of human beings [1]. Inventions that involve the commercial exploitation of human embryos for purposes like industrial or commercial use are also excluded.
- Plant and Animal Varieties: While plant and animal varieties are not patentable per se, patent protection can be granted for plant or animal cells, genes, or isolated plant or animal parts that have been genetically modified or for processes that produce them [1].
- Diagnostic Methods: Diagnostic methods practiced directly on the human or animal body are generally excluded from patentability. However, methods for diagnosing diseases in vitro (e.g., using blood samples) can be patentable if they meet the criteria of novelty, inventive step, and industrial applicability [1]. This often involves patenting specific reagents, probes, or analytical techniques used in the diagnosis.
What are the Key Challenges in Claiming Biopharmaceutical Inventions in Austria?
Drafting strong and defensible claims for biopharmaceutical inventions in Austria presents distinct challenges, primarily related to defining the scope of protection adequately while avoiding prior art and meeting the enablement requirement.
Claim Drafting Challenges:
- Broad vs. Narrow Claims: A fundamental tension exists between drafting broad claims that offer extensive market protection and narrow claims that are more likely to be found valid and infringed. For novel compounds, generic claims covering a class of related structures may be desirable, but they must be supported by sufficient experimental data to demonstrate enablement and non-obviousness across the entire claimed genus [1].
- Enablement Requirement: The patent application must describe the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art [1]. For complex biopharmaceuticals, this can involve providing detailed characterization data, synthesis protocols, purification methods, and functional assays. Insufficient enablement can lead to claims being deemed invalid.
- Written Description Requirement: Related to enablement, the claims must be supported by the description. The description must clearly and adequately disclose the invention that is claimed. For biopharmaceuticals, this can be particularly challenging when claiming future discoveries or broad structural classes of compounds [1].
- Prior Art Searches and Freedom to Operate: Comprehensive prior art searches are essential to identify existing technologies that could anticipate or render obvious the claimed invention. Freedom-to-operate analyses are also critical to ensure that the intended commercialization does not infringe existing patents. The increasing volume of biopharmaceutical patent filings necessitates rigorous search strategies.
- Sufficiency of Data for Second Medical Use Claims: Claims for new medical uses of known compounds (second medical use claims) require specific evidence to establish novelty and inventive step. The claim must be directed to the new use itself, not just the known compound. Demonstrating a new therapeutic effect or an improved therapeutic profile is typically required [1].
- "Markush" Claims: Claims that define a group of compounds by using a generic formula (Markush claims) are common in biopharmaceutical patenting. However, their validity depends on the chemical diversity within the Markush group and whether the applicant has provided sufficient support for all possible variations. Inadequate support can lead to claims being narrowed or invalidated [1].
How is Inventive Step Assessed for Biopharmaceutical Patents in Austria?
The assessment of inventive step for biopharmaceutical patents in Austria, as guided by EPO practice, is a complex, multi-step process. It typically involves a problem-solution approach.
Problem-Solution Approach for Inventive Step:
- Determine the closest prior art: This is the single most promising prior art document that discloses subject matter closest to the invention and shares most of the essential features.
- Determine the objective technical problem: Based on the closest prior art and the invention as claimed, the objective technical problem is formulated. This problem should be a technical problem that the invention, when considered in light of the closest prior art, solves. It is not the problem perceived by the inventor but one that is objectively derivable.
- Assess whether the invention is obvious to the person skilled in the art: The skilled person, starting from the closest prior art and faced with the objective technical problem, would or would not have arrived at the claimed invention without exercising inventive activity. This assessment considers whether the prior art suggests or teaches the modifications or combinations of features leading to the invention.
Specific Considerations for Biopharmaceuticals:
- "Obvious to Try" Scenarios: Courts and patent offices are cautious about inventions that are merely "obvious to try." If the skilled person had a reasonable expectation of success in pursuing a particular modification or direction based on the prior art, the invention may lack an inventive step. For example, if prior art suggests that a range of structurally similar compounds are all likely to have a particular activity, and the claimed invention falls within that range, it may not be considered inventive.
- Unexpected Technical Effects: A strong indicator of inventive step is the demonstration of an unexpected technical effect. This could be a significantly improved efficacy, reduced toxicity, a novel mechanism of action, or improved pharmacokinetic properties compared to known compounds or treatments [1].
- Biotechnology Specifics: For genetic sequences, inventive step often relies on demonstrating a specific function or utility that was not previously known or suggested by the prior art. For antibodies, inventive step can be based on unique binding characteristics, therapeutic efficacy, or improved production methods.
- Post-Filing Data: While inventive step is assessed based on the state of the art at the filing date, post-filing data can sometimes be used to corroborate an inventive step that was already implicitly present at the filing date, particularly to demonstrate an unexpected technical effect.
What are the Implications of the Unitary Patent and Unified Patent Court on Austrian Biopharmaceutical Patents?
The introduction of the Unitary Patent (UP) and the Unified Patent Court (UPC) has significant implications for patent protection and enforcement in Austria and across participating EU member states.
Impact of Unitary Patent and UPC:
- Unified Protection: A Unitary Patent provides single, uniform patent protection for 17 EU member states (as of its launch), including Austria. This eliminates the need for validation in each individual country, simplifying the process and potentially reducing costs [2].
- Centralized Enforcement: The UPC offers a single court system for infringement and validity actions concerning Unitary Patents and traditional European Patents that have not opted out. This allows for pan-European injunctions and damages awards, or revocations, in a single proceeding [2].
- Opt-Out Mechanism: Proprietors of traditional European Patents can choose to "opt-out" of the UPC system for a transitional period (seven years, renewable). This means that these patents will continue to be litigated before national courts, including the Austrian Patent Court.
- Strategic Considerations: Companies must strategically decide whether to pursue Unitary Patents or traditional European Patents. The choice depends on territorial coverage needs, risk assessment regarding potential invalidation actions, and enforcement strategies. For biopharmaceutical companies operating across multiple EU markets, the UP could streamline protection and enforcement.
- Austria's Role: Austria is one of the participating states in the UP and UPC system. Patent litigation formerly handled by Austrian national courts for European Patents may now fall under the jurisdiction of the UPC if the patent is not opted out.
- Revocation Risk: A key concern with the UPC is the potential for a single revocation action to invalidate a patent across all designated UP territories. This contrasts with national court proceedings where revocation is limited to the specific country.
What are the Trends in Enforcement and Litigation for Biopharmaceutical Patents in Austria?
Enforcement of biopharmaceutical patents in Austria traditionally occurred through national courts. The advent of the UPC is set to transform this landscape.
Trends in Enforcement:
- Infringement Assessment: Infringement occurs when a third party makes, uses, offers, sells, or imports a patented invention without the patent holder's permission. For biopharmaceuticals, this can involve the unauthorized production or sale of patented drugs, the use of patented diagnostic methods, or the unauthorized application of patented manufacturing processes.
- Validity Challenges: Patent holders must be prepared for validity challenges, typically based on prior art rendering the invention obvious or lacking novelty, or on issues of insufficient disclosure or enablement.
- Preliminary Injunctions: Patent holders may seek preliminary injunctions to prevent ongoing infringement during litigation. The grant of such injunctions depends on factors like the likelihood of success on the merits and the potential for irreparable harm.
- Damages: If infringement is found, patent holders can seek damages to compensate for their losses. This can include lost profits or a reasonable royalty.
- Focus on Essential Features: Litigation often centers on whether the alleged infringing product or process includes all the essential features of the patent claims.
- Impact of UPC on Litigation: The UPC is expected to lead to more streamlined and potentially faster pan-European patent litigation. However, it also introduces new procedural rules and strategic considerations. The early decisions of the UPC will shape future litigation trends.
- Bio-similar and Bio-orphan Drug Litigation: Litigation in the biopharmaceutical sector often involves disputes between originators and manufacturers of biosimilars, focusing on patent expiry, data exclusivity, and inventive step of process patents. Litigation around orphan drugs may also involve disputes over market exclusivity and patent scope.
Key Takeaways
- Biopharmaceutical patentability in Austria hinges on novelty, inventive step, and industrial applicability, with significant influence from EPC guidelines.
- Discoveries of biological material require isolation and demonstration of function to be patentable inventions.
- Claim scope requires careful drafting to balance broad protection with enablement and prior art limitations, particularly for generic compounds and second medical uses.
- Inventive step is assessed via a problem-solution approach, with unexpected technical effects being a key indicator.
- The Unitary Patent and Unified Patent Court system introduce new avenues for unified protection and centralized enforcement across participating EU states, including Austria.
- Patent enforcement will increasingly involve the UPC for non-opted-out European Patents, leading to pan-European litigation strategies.
FAQs
-
Are naturally occurring human genes patentable in Austria?
Naturally occurring human genes are not patentable. However, if a gene is isolated or obtained by means of a technical process and its function is identified, it can be considered an invention and potentially patentable.
-
What is the primary difference between a Unitary Patent and a traditional European Patent validated in Austria?
A Unitary Patent provides single, uniform protection across multiple participating EU member states, including Austria, validated through a single request. A traditional European Patent validated in Austria requires national validation procedures and is subject to national patent law and dispute resolution unless opted into the UPC system.
-
Can a method for diagnosing a disease in humans be patented in Austria?
Diagnostic methods practiced directly on the human body are excluded from patentability. However, in vitro diagnostic methods, such as those performed on a blood sample in a laboratory, can be patentable if they meet the general patentability criteria.
-
What is the "problem-solution" approach in assessing inventive step for biopharmaceutical patents?
It is a methodology where the closest prior art is identified, an objective technical problem is formulated, and then it is assessed whether a person skilled in the art would have arrived at the invention without inventive activity when faced with that problem and the closest prior art.
-
Does the Unified Patent Court (UPC) apply to all Austrian biopharmaceutical patents?
The UPC has jurisdiction over Unitary Patents and traditional European Patents that have not been opted out of the system. Patents that have been opted out will continue to be litigated before national courts, including Austrian courts.
Citations
[1] Austrian Patent Act (Patentgesetz - PatG). (As amended). Retrieved from the official publication of Austrian legislation.
[2] European Union. (n.d.). Unitary patent. Retrieved from the European Union Intellectual Property Office website.
